Hematopoietic Growth Factors: Use of Thrombopoietin Receptor Agonists in Patients with Cancer
Since there is currently no FDA-approved treatment for CIT, clinicians must make decisions on the appropriate incorporation of thrombopoietin receptor agonists (TPO-RAs) into clinical practice. Increased education and awareness of the available treatment options, including TPO-RA, will help to ensure the acceptance and use of these agents in supportive oncology care for patients with CIT.
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2022

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA).

NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN.

New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Challenges remain in the acceptance of biosimilar medications by physicians, payers, and patients in the U.S., similar to the challenges faced by generic drugs when they were first introduced to the market.

Recorded Presentation from the NCCN Pharmacy Updates: Role of Biosimilar Agents in Myeloid Growth Factor Therapy

Join Mary S. Mably, RPh, BCOP, from University of Wisconsin Carbone Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Series on the topic Role of Biosimilar Agents in Myeloid Growth Factor Therapy.

NCCN Pharmacy Updates: Role of Biosimilar Agents in Myeloid Growth Factor Therapy

Join Mary S. Mably, RPh, BCOP, from University of Wisconsin Carbone Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Series on the topic Role of Biosimilar Agents in Myeloid Growth Factor Therapy.

Myeloid Growth Factors Revisited

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Subscribe to RSS - Myeloid Growth Factors